Who
Joseph M. Lobacki
Director
Company insider
Files Form 4 as: Director, Sutro Biopharma; Executive VP & CCO, Verastem; Director, Celator Pharmaceuticals; Chief Commercial Officer, Medivation; SVP & Chief Commercial Officer, Micromet.
In numbers
- Trades disclosed
- 27
- Buys
- 2
- Sells
- 1
- Bought
- $66K
- Sold
- $143K
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 1 Dec 2011
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Dec 2025filed 29 Dec 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 6 Jun 2022filed 8 Jun 2022 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 3 Jun 2021filed 7 Jun 2021 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 5 Jun 2020filed 8 Jun 2020 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 17 Jun 2019filed 19 Jun 2019 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,610 at $0.00 | filing |
| 3 Jan 2019filed 7 Jan 2019 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 3 Jan 2019filed 7 Jan 2019 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 28 Sep 2018filed 2 Oct 2018 | VSTM VerastemBiotechnology | SEC FORM 4 Bought | $22K3,000 at $7.30 | filing |
| 26 Sep 2018filed 27 Sep 2018 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,033 at $0.00 | filing |
| 8 Jun 2018filed 12 Jun 2018 | VSTM VerastemBiotechnology | SEC FORM 4 Bought | $45K7,700 at $5.79 | filing |
| 3 Jan 2018filed 5 Jan 2018 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 12 Jul 2016filed 12 Jul 2016 | Celator Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $750K28,000 at $26.78 | filing |
| 12 Jul 2016filed 12 Jul 2016 | Celator Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $384K14,000 at $27.45 | filing |
| 4 Jan 2016filed 5 Jan 2016 | Medivation | SEC FORM 4 Sold | $143K3,065 at $46.50 | filing |
| 11 Jun 2015filed 12 Jul 2016 | Celator Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | $387K14,000 at $27.65 | filing |
News
Verastem (NASDAQ:VSTM) Stock Price Target Raised at MizuhoVSTM · tickerreport.com · 16 Oct 2026Verastem (NASDAQ:VSTM) Shares Gap Up – Time to Buy?VSTM · tickerreport.com · 14 Oct 2026Verastem (NASDAQ:VSTM) Stock Falls 7% – Here's What HappenedVSTM · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Joseph M. Lobacki; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.